<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-140253" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Peripheral Ulcerative Keratitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fu</surname>
            <given-names>Lanxing</given-names>
          </name>
          <aff>Kent &#x00026; Canterbury Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jones</surname>
            <given-names>Sophie</given-names>
          </name>
          <aff>King's College Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lanxing Fu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sophie Jones declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-140253.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Peripheral ulcerative keratitis (PUK) is an inflammatory condition affecting the juxtalimbal cornea.&#x000a0;The pathophysiology involves a complex interplay between host autoimmunity, the anatomy and physiology of the peripheral cornea, and environmental influences. The underlying cause&#x000a0;may be local or systemic, infectious or noninfectious. Progressive stromal lysis can cause corneal perforation, which is an emergency. PUK occurring in patients with an underlying autoimmune disease&#x000a0;carries significant morbidity and mortality.</p>
        <p>Management for&#x000a0;PUK includes aggressive topical corticosteroid therapy to reduce inflammation and prevent corneal perforation, alongside the use of antibiotics for secondary infections. Systemic immunosuppressants may also be considered in cases associated with systemic diseases.</p>
        <p>This activity for healthcare professionals is designed to enhance learners' proficiency in evaluating and managing PUK. Participants gain a broader grasp of the condition's risk factors, pathogenesis, symptomatology, and best diagnostic and therapeutic strategies. Greater competence enables clinicians to work within an interprofessional team caring for patients with PUK.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical features indicative of&#x000a0;peripheral ulcerative&#x000a0;keratitis.</p></list-item><list-item><p>Develop clinically guided diagnostic approaches for&#x000a0;peripheral ulcerative&#x000a0;keratitis.</p></list-item><list-item><p>Implement individualized, evidence-based management plans for&#x000a0;peripheral ulcerative&#x000a0;keratitis cases.</p></list-item><list-item><p>Collaborate with the interprofessional team to educate, treat, and monitor patients with peripheral ulcerative&#x000a0;keratitis to improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140253&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140253">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-140253.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Peripheral ulcerative keratitis (PUK) is a&#x000a0;disorder affecting the juxtalimbal cornea, classically presenting with epithelial defects and stromal lysis. This rare but severe inflammatory condition results&#x000a0;from a complex interplay between host autoimmunity, the anatomy and physiology of the peripheral cornea, and environmental factors. The underlying cause could be local or systemic, infectious or noninfectious. PUK may be due to vasculitides or collagen vascular disease, rheumatoid arthritis, granulomatosis with polyangiitis (GPA), and systemic lupus erythematosus (SLE) can account for up to 53% of PUK cases.<xref ref-type="bibr" rid="article-140253.r1">[1]</xref>&#x000a0;PUK with scleritis&#x000a0;has a poor prognosis. Progressive stromal lysis can cause corneal perforation and, in patients with an underlying autoimmune disease,&#x000a0;carries significant morbidity and mortality.</p>
        <p>PUK without systemic association is known as Mooren ulcer (MU) and&#x000a0;comprises 31.5%&#x000a0;of&#x000a0;PUK&#x000a0;cases.<xref ref-type="bibr" rid="article-140253.r2">[2]</xref>&#x000a0;Bowman first described&#x000a0;this condition in 1849, followed by McKenzie in 1854,&#x000a0;who called it an "ulcus roden" of the cornea.<xref ref-type="bibr" rid="article-140253.r3">[3]</xref>&#x000a0;Mooren ulcer occurs in the absence of scleritis and is a diagnosis of exclusion. Clinical signs begin in the peripheral cornea and progress centrally and circumferentially, with a distinctive overhanging edge.</p>
        <p>Quick recognition of PUK is&#x000a0;crucial, as it can be the first presenting feature of a life-threatening systemic disease.&#x000a0;Meticulous clinical investigation and&#x000a0;interprofessional&#x000a0;management are required to ensure safe patient outcomes.<xref ref-type="bibr" rid="article-140253.r4">[4]</xref></p>
        <p>The cornea has several layers, including the epithelium, Bowman membrane, stroma, Descemet membrane, and endothelium.&#x000a0;The peripheral cornea&#x000a0;has a rich vascular supply and an abundance&#x000a0;of immune cells, making it more vulnerable to immune-mediated damage and&#x000a0;inflammatory disorders&#x000a0;like PUK.<xref ref-type="bibr" rid="article-140253.r5">[5]</xref>&#x000a0;Most PUK cases&#x000a0;arise in the setting of an&#x000a0;autoimmune disorder. However,&#x000a0;PUK may also result from infections, including herpes simplex virus&#x000a0;and bacterial keratitis, ocular surface disorders, trauma, or surgical procedures. The natural history of PUK involves progression from peripheral corneal inflammation and thinning to ulceration, which can lead to perforation if left untreated.<xref ref-type="bibr" rid="article-140253.r6">[6]</xref> PUK may be staged based on the severity of corneal involvement. Without appropriate management, PUK can cause severe complications and may persist for months or even years with periods of remission and exacerbation.<xref ref-type="bibr" rid="article-140253.r7">[7]</xref></p>
        <p>The pattern of spread in PUK usually involves local extension along the peripheral cornea, with the potential for centripetal spread toward the central cornea in severe cases. PUK often presents unilaterally, and bilateral involvement is&#x000a0;associated with&#x000a0;systemic autoimmune&#x000a0;disease. Investigations for PUK include slit-lamp examination with fluorescein staining to evaluate epithelial defects, microbial cultures to rule out infections, and testing for systemic autoimmune markers like antinuclear antibodies (ANA), rheumatoid factor, and antineutrophil cytoplasmic antibodies (ANCA). Anterior segment optical coherence tomography may also be used to assess corneal thickness.<xref ref-type="bibr" rid="article-140253.r8">[8]</xref></p>
        <p>Management of PUK involves both medical and surgical approaches. Topical steroids and immunomodulatory agents, such as cyclosporine&#x000a0;and tacrolimus, control local inflammation, while systemic immunosuppressants, including methotrexate and biologics, are required for treating underlying autoimmune conditions. Surgical interventions, such as amniotic membrane transplantation&#x000a0;and corneal transplantation, may be necessary in cases of severe corneal damage or perforation. Referral to a rheumatologist for managing associated systemic diseases is essential to ensure long-term control and prevent recurrence.</p>
        <p>The prognosis for PUK varies&#x000a0;with&#x000a0;severity and the timeliness of treatment. If detected early and treated aggressively, patients can have a favorable outcome and preserve vision. However, delayed treatment may result in corneal perforation, permanent vision loss,&#x000a0;and secondary infections.<xref ref-type="bibr" rid="article-140253.r9">[9]</xref></p>
      </sec>
      <sec id="article-140253.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Table 1 summarizes the variety of ocular (local) and systemic disorders that can lead to PUK.&#x000a0;Almost half of all noninfectious cases of PUK are associated with a connective tissue disorder, of which rheumatoid arthritis is the most common. PUK affects both eyes in nearly half of all late-stage rheumatoid arthritis cases. Tauber et al report that 34% of eyes with noninfectious PUK&#x000a0;have an associated&#x000a0;rheumatoid arthritis.<xref ref-type="bibr" rid="article-140253.r10">[10]</xref>&#x000a0;PUK is also a relatively common presenting feature of GPA, a systemic vasculitis that&#x000a0;affects the sinuses, nose, throat, lungs, and kidneys. GPA-associated PUK is due to a necrotizing vasculitis affecting the anterior ciliary or perilimbal arteries.&#x000a0;</p>
        <p>PUK manifests&#x000a0;with crescentic stromal thinning, inflammatory cells in the juxtalimbal cornea, and an epithelial defect.&#x000a0;Infections can&#x000a0;involve the peripheral cornea without&#x000a0;resulting in PUK. However, infection&#x000a0;constitutes 19.7% of all PUK cases and must be ruled out when the ocular&#x000a0;disorder is identified.&#x000a0;Various microorganisms may cause PUK, including bacteria, viruses, fungi, and <italic toggle="yes">Acanthamoeba</italic> spp.</p>
        <table-wrap id="article-140253.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1. Causes of PUK</title>
          </caption>
          <table style="width: 515px; margin-left: auto; margin-right: auto; height: 737px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 231.598px; text-align: center;" rowspan="1" colspan="1">
<p><bold><bold>Systemic Causes</bold></bold></p>
</td>
                <td style="width: 195.22px; text-align: center;" rowspan="1" colspan="1">
<p><bold><bold><bold><bold>Ocular&#x000a0;Causes</bold></bold></bold></bold></p>
</td>
              </tr>
              <tr>
                <td style="width: 231.598px;" rowspan="1" colspan="1">
<p><bold>Infection:</bold></p>
<list list-type="bullet"><list-item><p>Varicella zoster virus</p></list-item><list-item><p>Viral hepatitis</p></list-item><list-item><p>Tuberculosis</p></list-item><list-item><p>Syphilis</p></list-item><list-item><p>Lyme Disease</p></list-item><list-item><p><italic toggle="yes">Salmonella</italic> gastroenteritis</p></list-item><list-item><p>Bacillary dysentery</p></list-item><list-item><p>Gonococcal arthritis</p></list-item><list-item><p>Cat scratch disease</p></list-item><list-item><p>Parasitic infections</p></list-item><list-item><p>Parinaud oculoglandular fever</p></list-item></list>
<p><bold>Autoimmune:</bold></p>
<list list-type="bullet"><list-item><p>Rheumatoid arthritis</p></list-item><list-item><p>GPA</p></list-item><list-item><p>Polyarteritis nodosa</p></list-item><list-item><p>Microscopic polyangiitis</p></list-item><list-item><p>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</p></list-item><list-item><p>Sj&#x000f6;gren syndrome</p></list-item><list-item><p>Sarcoidosis</p></list-item><list-item><p>Relapsing polychondritis</p></list-item><list-item><p>Be&#x000e7;het&#x000a0;syndrome</p></list-item><list-item><p>Giant cell&#x000a0;arteritis</p></list-item><list-item><p>Takayasu arteritis</p></list-item><list-item><p>SLE</p></list-item><list-item><p>Inflammatory bowel disease</p></list-item><list-item><p>Autoimmune hepatitis</p></list-item><list-item><p>Dermatological:
<list list-type="bullet"><list-item><p>Acne rosacea</p></list-item><list-item><p>Cicatricial pemphigoid</p></list-item><list-item><p>Stevens-Johnson syndrome</p></list-item><list-item><p>Pyoderma gangrenosum</p></list-item></list>
</p></list-item></list>
<p><bold>Other Systemic:</bold></p>
<list list-type="bullet"><list-item><p>Malignancies</p></list-item><list-item><p>Hemolytic uremic syndrome</p></list-item><list-item><p>Pharmaceuticals</p></list-item><list-item><p>Gout</p></list-item></list>
</td>
                <td style="width: 195.22px;" rowspan="1" colspan="1">
<p><bold>Infection:</bold></p>
<list list-type="bullet"><list-item><p><italic toggle="yes">Staphylococcus</italic></p></list-item><list-item><p><italic toggle="yes">Streptococcus</italic></p></list-item><list-item><p><italic toggle="yes">Gonococcus</italic></p></list-item><list-item><p><italic toggle="yes">Moraxella</italic></p></list-item><list-item><p><italic toggle="yes">Haemophilus</italic></p></list-item><list-item><p>Herpes simplex virus</p></list-item><list-item><p>Herpes zoster</p></list-item><list-item><p><italic toggle="yes">Pseudomonas aeruginosa</italic></p></list-item><list-item><p><italic toggle="yes">Chlamydia trachomatis</italic></p></list-item><list-item><p>Filamentous fungi</p></list-item><list-item><p>Dematicious fungi</p></list-item><list-item><p><italic toggle="yes">Acanthamoeba</italic></p></list-item><list-item><p>Epstein Barr virus</p></list-item><list-item><p><italic toggle="yes">Pythium insidiosum</italic></p></list-item></list>
<p><bold>Autoimmune:</bold></p>
<list list-type="bullet"><list-item><p>Mooren ulcer</p></list-item><list-item><p>Allograft rejection</p></list-item></list>
<p><bold>Trauma:</bold></p>
<list list-type="bullet"><list-item><p>Corneal penetrating injury</p></list-item><list-item><p>Chemical injuries</p></list-item><list-item><p>Thermal burns</p></list-item><list-item><p>Radiation injuries</p></list-item><list-item><p>Eyelid or margin abnormalities</p></list-item><list-item><p>Ectropion or entropion</p></list-item><list-item><p>Eyelid tumor</p></list-item><list-item><p>Trichiasis</p></list-item><list-item><p>Lagophthalmos</p></list-item></list>
<p><bold>Neurological:</bold></p>
<list list-type="bullet"><list-item><p>Metaherpetic</p></list-item><list-item><p>Xerophthalmia</p></list-item><list-item><p>Neuroparalytic</p></list-item></list>
<p><bold>Iatrogenic:</bold></p>
<list list-type="bullet"><list-item><p>Post&#x02013;laser-assisted <italic toggle="yes">in situ</italic> keratomileusis</p></list-item><list-item><p>Posttrabeculectomy</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Mooren Ulcer </bold>
</p>
        <p>This condition is a diagnosis of exclusion and is often&#x000a0;accompanied by&#x000a0;severe pain.<xref ref-type="bibr" rid="article-140253.r11">[11]</xref>&#x000a0;Complications such as anterior uveitis, secondary infection, cataract, glaucoma, and corneal perforation may develop in 35% to 40% of patients. Watson and colleagues have described&#x000a0;3 clinical subtypes.<xref ref-type="bibr" rid="article-140253.r12">[12]</xref></p>
        <p>
<bold>Type 1 - Unilateral Mooren Ulceration</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Unilateral</p>
          </list-item>
          <list-item>
            <p>Older than 60 years</p>
          </list-item>
          <list-item>
            <p>Female patients</p>
          </list-item>
          <list-item>
            <p>Severe pain</p>
          </list-item>
          <list-item>
            <p>Rapid progression</p>
          </list-item>
          <list-item>
            <p>Poor prognosis, recurrence</p>
          </list-item>
          <list-item>
            <p>Complications rare</p>
          </list-item>
        </list>
        <p>
<bold>Type 2 - Bilateral Aggressive Mooren Ulcer</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bilateral</p>
          </list-item>
          <list-item>
            <p>Young (14-40 years)</p>
          </list-item>
          <list-item>
            <p>Male patients</p>
          </list-item>
          <list-item>
            <p>Mild-to-moderate pain</p>
          </list-item>
          <list-item>
            <p>Slow progression but&#x000a0;aggressive initially</p>
          </list-item>
          <list-item>
            <p>Poor prognosis, recurrence</p>
          </list-item>
          <list-item>
            <p>Complications common</p>
          </list-item>
        </list>
        <p>
<bold>Type 3 - Bilateral Indolent Mooren Ulcer</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bilateral</p>
          </list-item>
          <list-item>
            <p>Middle-aged (mid-50s)</p>
          </list-item>
          <list-item>
            <p>No gender predilection</p>
          </list-item>
          <list-item>
            <p>Mild pain</p>
          </list-item>
          <list-item>
            <p>Slow progression</p>
          </list-item>
          <list-item>
            <p>Better prognosis, recurrence rare</p>
          </list-item>
          <list-item>
            <p>Complications rare</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-140253.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>In the United Kingdom, estimates for PUK incidence range from 0.2 to 3 patients per million annually.<xref ref-type="bibr" rid="article-140253.r13">[13]</xref><xref ref-type="bibr" rid="article-140253.r14">[14]</xref><xref ref-type="bibr" rid="article-140253.r15">[15]</xref>&#x000a0;Female individuals are more likely to be affected generally, although this trend is reversed for Mooren ulcers.<xref ref-type="bibr" rid="article-140253.r16">[16]</xref>&#x000a0;Evidence does not support a racial or ethnic predilection for PUK, and the associated cause influences both the likelihood and the age at the initial presentation. Classification is generally clinical, enabling&#x000a0;healthcare practitioners to choose appropriate investigations and treatments that target the underlying etiology.</p>
        <list list-type="bullet">
          <list-item>
            <p>Incidence and prevalence:&#x000a0;PUK is considered a rare condition globally, affecting fewer than 5 individuals per 100,000 annually.&#x000a0;PUK is most commonly seen in association with systemic autoimmune diseases like rheumatoid arthritis or systemic vasculitis.<xref ref-type="bibr" rid="article-140253.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Sex distribution:&#x000a0;Studies indicate a slight female predominance, particularly in cases linked to autoimmune conditions.&#x000a0;This trend reflects the higher prevalence of&#x000a0;autoimmunity in women.<xref ref-type="bibr" rid="article-140253.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Age groups:&#x000a0;PUK primarily affects middle-aged and older adults, especially those in their 6th and 7th decade.&#x000a0;However, PUK can occur in younger individuals if associated with autoimmune diseases.<xref ref-type="bibr" rid="article-140253.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Global distribution:&#x000a0;The condition is reported worldwide, with higher frequencies in populations with higher rates of autoimmune disorders. In developing regions, infectious causes, such as bacterial or fungal keratitis, may be more common triggers for PUK than autoimmune disorders.<xref ref-type="bibr" rid="article-140253.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>Understanding the epidemiology helps identify at-risk populations and target preventative or early intervention strategies.</p>
      </sec>
      <sec id="article-140253.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Several significant differences between the central and peripheral cornea make it susceptible to inflammation, ulceration, and furrowing. The peripheral cornea is the transition zone between the cornea, conjunctiva, episclera, and sclera, with a combination of histologic features.<xref ref-type="bibr" rid="article-140253.r21">[21]</xref>&#x000a0;Neural innervation and sensitivity are reduced in the peripheral compared with the central cornea.<xref ref-type="bibr" rid="article-140253.r22">[22]</xref> The thickness of the peripheral cornea is around 1000 &#x003bc;m,&#x000a0;which is greater than that of&#x000a0;the central cornea,&#x000a0;which is&#x000a0;550 &#x003bc;m. Epithelial cells adhere more tightly to the corneal basement membrane and stroma in the periphery than in other areas.<xref ref-type="bibr" rid="article-140253.r23">[23]</xref></p>
        <p>The reservoir of corneal epithelial stem cells and the mitogenic activity of corneal endothelial cells&#x000a0;are also highest in the peripheral cornea. An imbalance between collagenase and tissue inhibitor activity&#x000a0;has been hypothesized to cause the&#x000a0;loss of corneal integrity and increased corneal matrix turnover. Elevated levels of matrix metalloproteinases, which degrade the extracellular matrix, along with reduced tissue metalloproteinase inhibitors, can result in increased keratolysis.<xref ref-type="bibr" rid="article-140253.r24">[24]</xref><xref ref-type="bibr" rid="article-140253.r25">[25]</xref></p>
        <p>The central cornea is avascular and derives most of its nutrition through the tear film and aqueous humor. In contrast, the peripheral cornea has a well-developed vascular and lymphatic supply,&#x000a0;with perilimbal vessels extending 0.5 mm into the cornea.&#x000a0;This area is a source of immunoglobulins, macrophages, lymphocytes, plasma cells, and other immune cells that mediate&#x000a0;the inflammatory process.<xref ref-type="bibr" rid="article-140253.r26">[26]</xref>&#x000a0;</p>
        <p>A combination of&#x000a0;humoral and cellular immune mechanisms is often involved in PUK's pathogenesis. In PUK secondary to rheumatoid arthritis, autoantibodies and self-antigens combine to form immune complexes, which activate B cells and complement proteins. B cells can further stimulate T cells to secrete cytokines associated with rheumatoid arthritis. The combination of angiogenesis and immune cell clusters contributes to pannus formation in PUK.<xref ref-type="bibr" rid="article-140253.r27">[27]</xref></p>
      </sec>
      <sec id="article-140253.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathology&#x000a0;is vital in diagnosing PUK&#x000a0;and understanding its underlying causes.&#x000a0;The key findings of microscopic tissue examination are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Inflammatory cell infiltration:&#x000a0;Dense infiltration of neutrophils, lymphocytes, and plasma cells is often observed in the corneal stroma, particularly in autoimmune-related PUK cases. This inflammation leads to tissue destruction and corneal thinning.</p>
          </list-item>
          <list-item>
            <p>Necrosis and stromal loss:&#x000a0;Severe&#x000a0;corneal epithelium and stroma&#x000a0;necrosis are hallmarks of active PUK.&#x000a0;Necrotic tissue may be observed, especially at the periphery of the cornea.<xref ref-type="bibr" rid="article-140253.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Immune complex deposition:&#x000a0;In systemic autoimmune diseases like rheumatoid arthritis, evidence of immune complex deposition (immunoglobulins G&#x000a0;and M and complement components) may be seen along the corneal blood vessels. Immune complex deposition&#x000a0;contributes&#x000a0;to inflammation.<xref ref-type="bibr" rid="article-140253.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Angiogenesis:&#x000a0;In longstanding cases, neovascularization may be observed within the peripheral cornea. This feature is a sign of chronic inflammation and healing attempts.<xref ref-type="bibr" rid="article-140253.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>Histopathological findings help confirm the diagnosis and differentiate PUK from other causes of peripheral corneal thinning, guiding targeted treatment strategies.</p>
      </sec>
      <sec id="article-140253.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>PUK is more often unilateral&#x000a0;than bilateral at the initial presentation.&#x000a0;Bilateral PUK is often asymmetrical and is associated with systemic disease. Patients typically complain of ocular pain, photophobia, and tearing. The eyes are injected&#x000a0;and appear red. Pain&#x000a0;is variable&#x000a0;but comprises an important feature of PUK.&#x000a0;In Mooren ulcers, the pain is often out of proportion to the clinical signs. Reduction in vision is due to inflammation and&#x000a0;may be mild or severe.&#x000a0;</p>
        <p>The classic clinical signs of&#x000a0;PUK include peripheral crescentic ulceration, superimposed epithelial defect, stromal loss, and limbal infiltrates with an overhanging edge (see <bold>Image.&#x000a0;</bold>Peripheral Ulcerative Keratitis in&#x000a0;Rheumatoid&#x000a0;Arthritis). When PUK is associated with a systemic disease, the inflammation&#x000a0;may also involve the surrounding conjunctiva, episclera, and sclera, with additional nodular or necrotizing scleritis.&#x000a0;Persistent&#x000a0;inflammation and stromal lysis can progress to corneal perforation, and iris tissue&#x000a0;is clinically visible as a "plug" at&#x000a0;the perforation site.&#x000a0;Perforation&#x000a0;is an ocular emergency.&#x000a0;Chronic PUK with peripheral thinning and corneal vascularization results in significant irregular astigmatism, scarring, and reduced vision.&#x000a0;</p>
        <p>Mooren ulcer&#x000a0;arises from an unknown cause.&#x000a0;Please refer to the&#x000a0;<bold>Etiology</bold> section for descriptions of the 3 types of Mooren ulcer by Watson et al.</p>
        <p>A detailed clinical history and physical examination can identify most causes of PUK.&#x000a0;Information to note during&#x000a0;history taking&#x000a0;includes&#x000a0;associated constitutional symptoms, musculoskeletal pain, as well as gastrointestinal, respiratory, skin, cardiac, and neurological signs and symptoms.&#x000a0;</p>
        <p>
<bold>Clinical History</bold>
</p>
        <p>Patients often report sudden onset of pain, redness, photophobia, and tearing in the affected eye(s).&#x000a0;A history of autoimmune disease, such as rheumatoid arthritis, GPA,&#x000a0;or SLE, is common. The progression&#x000a0;may be rapid, leading to corneal thinning. A history of&#x000a0;recent eye infections, autoimmune disorders, or previous ocular surgeries may increase the risk for PUK. Although less common, trauma and contact lens overuse&#x000a0;predispose&#x000a0;to peripheral corneal ulceration.<xref ref-type="bibr" rid="article-140253.r31">[31]</xref></p>
        <p>
<bold> Physical Examination</bold>
</p>
        <p>The hallmark finding in PUK is peripheral corneal thinning, often with associated ulceration. The lesion usually affects the peripheral 2 to 4 mm of the cornea. Severe limbal and conjunctival hyperemia (redness), inflammation, and scleral involvement may be observed. Signs of impending corneal perforation may be&#x000a0;seen in advanced cases, with visible Descemet membrane or prolapse of intraocular contents. Gray-white stromal infiltrates may be&#x000a0;adjacent to the thinning area,&#x000a0;suggesting&#x000a0;active inflammation. Anterior uveitis or hypopyon may be present in severe cases, indicating a significant inflammatory response.</p>
        <p>
<bold> Associated Findings</bold>
</p>
        <p>In some cases, patients may also have accompanying scleritis or episcleritis, which can signal underlying systemic vasculitis. While unilateral PUK is more common, patients with systemic autoimmune diseases may present with bilateral involvement.<xref ref-type="bibr" rid="article-140253.r32">[32]</xref></p>
        <p>
<bold>Importance of Systemic Evaluation</bold>
</p>
        <p>Given&#x000a0;PUK's strong association with systemic conditions, a thorough systemic history is essential to identify any underlying diseases that may need treatment alongside the ocular condition. A thorough history and physical examination can provide significant insights into the cause of PUK and guide appropriate management and intervention.<xref ref-type="bibr" rid="article-140253.r33">[33]</xref></p>
      </sec>
      <sec id="article-140253.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A well-structured physical examination can yield clues to the systemic cause of PUK. Findings&#x000a0;of subcutaneous nodules in the upper and lower limbs,&#x000a0;combined with rheumatoid factor and serum autoantibody detection, characterize rheumatoid arthritis. A saddle nose appearance and auricular pinnae deformity suggest relapsing polychondritis. This recurrent inflammatory disease of unknown etiology&#x000a0;produces&#x000a0;selective destructive inflammatory lesions of cartilaginous structures.<xref ref-type="bibr" rid="article-140253.r34">[34]</xref></p>
        <p>Features of SLE include oropharyngeal mucosal ulcers, a malar facial rash, facial&#x000a0;and scalp hypopigmentation or hyperpigmentation, and alopecia. A temporal headache with jaw claudication&#x000a0;is often reported&#x000a0;in giant cell arteritis. Raynaud phenomena may&#x000a0;manifest in SLE, Sj&#x000f6;gren syndrome, and progressive systemic sclerosis. GPA usually presents in the 4th or 5th decade, with a male preponderance of 3:2. The characteristic triad of necrotizing, granulomatous, and vasculitic lesions occurs in the respiratory tract and kidneys, causing focal segmental glomerulonephritis.<xref ref-type="bibr" rid="article-140253.r35">[35]</xref></p>
        <p>Several laboratory and radiographic tests are recommended to&#x000a0;diagnose PUK,&#x000a0;assess corneal damage, and identify underlying systemic diseases. Commonly employed tests recommended&#x000a0;by national and international guidelines include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Laboratory tests:</bold>&#x000a0;Important components to note in the&#x000a0;autoimmune panel include ANA, rheumatoid factor, and anti-citrullinated protein antibodies (ACPA). These markers help diagnose autoimmune conditions like rheumatoid arthritis and SLE. C-reactive protein and erythrocyte sedimentation rate&#x000a0;are elevated in systemic vasculitis and other autoimmune diseases associated with PUK. ANCA testing can help diagnose vasculitides like GPA.<xref ref-type="bibr" rid="article-140253.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Microbiological testing:</bold>&#x000a0;If infection is suspected, corneal scrapings with bacterial, fungal, and viral cultures can help identify the pathogen involved. Viruses such as herpes simplex&#x000a0;and varicella zoster may be detected using polymerase chain reaction.<xref ref-type="bibr" rid="article-140253.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Imaging studies:</bold>&#x000a0;Chest&#x000a0;radiography may reveal hilar lymphadenopathy or lung involvement&#x000a0;in patients with systemic&#x000a0;causes,&#x000a0;such as sarcoidosis&#x000a0;and tuberculosis. Sinus and orbital computed tomography is useful in cases of systemic granulomatous diseases, such as GPA.<xref ref-type="bibr" rid="article-140253.r38">[38]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Ocular investigations:&#x000a0;</bold>Anterior segment optical coherence tomography helps measure the depth of corneal thinning and assess&#x000a0;the extent of corneal damage. Corneal topography&#x000a0;assesses peripheral corneal irregularities and thinning.<xref ref-type="bibr" rid="article-140253.r39">[39]</xref>&#x000a0;Ultrasound biomicroscopy is useful&#x000a0;in anterior segment evaluation, especially if deep corneal or scleral involvement is suspected.</p>
          </list-item>
        </list>
        <p>
<bold>National and International Guidelines</bold>
</p>
        <p>The American Academy of Ophthalmology recommends an interprofessional approach involving ophthalmologists, rheumatologists, and infectious disease specialists. The European Society of Cataract and Refractive Surgeons provides guidelines for early detection and management of systemic autoimmune associations.</p>
      </sec>
      <sec id="article-140253.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Medical&#x000a0;Management: Aims and Strategy</bold>
</p>
        <p>A tailored approach is best, aiming to restore epithelial integrity, halt further stromal lysis, and prevent superinfections. PUK with confirmed noninfectious etiology&#x000a0;may be managed with a combination of topical lubricants, oral steroids,&#x000a0;and collagenase inhibitors. The role of topical corticosteroids is controversial.&#x000a0;These agents can increase the risk of corneal perforation in patients with autoimmune disease and should thus be considered cautiously.&#x000a0;</p>
        <p>Systemic immunosuppressants can take 4&#x000a0;to 6 weeks to take effect, but oral steroids may be prescribed in the interim.&#x000a0;Localized or systemic infection should be treated with the appropriate antimicrobials.&#x000a0;Corneal scrapings should be taken at the initial presentation for gram staining and microbiological evaluation.&#x000a0;Empirical therapy, such as 4th-generation fluoroquinolone monotherapy for bacterial keratitis, should be initiated afterward. Therapy&#x000a0;may be adjusted as needed once sensitivities are identified.</p>
        <p>Topical steroids&#x000a0;may be started to reduce the local inflammatory response after clinical improvement has been observed with&#x000a0;antimicrobial treatment.&#x000a0;However, topical steroid use should be delayed in cases of fungal infections. Topical acyclovir or ganciclovir should be started if a herpetic cause is suspected. Systemic infection requires specific protocols and shared care with the relevant specialties.&#x000a0;&#x000a0;</p>
        <p>
<bold>Peripheral Ulcerative Keratitis Associated with Systemic Autoimmunity</bold>
</p>
        <p>PUK management should include therapy specific to&#x000a0;the underlying cause. Some of these interventions are discussed below.</p>
        <p>
<bold>Rheumatoid arthritis</bold>
</p>
        <p>Current first-line management for rheumatoid arthritis includes systemic corticosteroids and cytotoxic agents like methotrexate (MTX).&#x000a0;Topical lubricants&#x000a0;help&#x000a0;protect&#x000a0;the ocular surface and encourage the epithelial healing of peripheral corneal ulcers.<xref ref-type="bibr" rid="article-140253.r40">[40]</xref>&#x000a0;Systemic therapy is initiated with rheumatology or immunology teams. Second-line agents include azathioprine and cyclophosphamide, which are used in severe, refractory PUK cases unresponsive to MTX.<xref ref-type="bibr" rid="article-140253.r41">[41]</xref>&#x000a0;</p>
        <p>
<bold>Granulomatosis with polyangiitis and polyarteritis nodosa</bold>
</p>
        <p>Aggressive treatment is needed for PUK secondary to GPA&#x000a0;or PAN. The first-line immunosuppressant agents for GPA include cyclophosphamide&#x000a0;and systemic corticosteroids, ideally started early in the disease course. Rituximab or cyclophosphamide, with or without other agents, is the most effective&#x000a0;in controlling&#x000a0;inflammation in GPA-associated PUK.<xref ref-type="bibr" rid="article-140253.r42">[42]</xref>&#x000a0;Cyclophosphamide and corticosteroids are&#x000a0;typically used in the remission phase, while rituximab is&#x000a0;administered&#x000a0;in the maintenance phase. A lack of response to cyclophosphamide&#x000a0;warrants consideration of rituximab. GPA-associated PUK presenting with necrotizing scleritis has a particularly poor visual prognosis, as this condition is&#x000a0;usually a sign of severe systemic vasculitis.<xref ref-type="bibr" rid="article-140253.r43">[43]</xref></p>
        <p>
<bold>Systemic lupus erythematosus</bold>
</p>
        <p>Foster et al have suggested that systemic vasculitis only develops in the latter stages of SLE. Systemic corticosteroids and a cytotoxic agent are used in SLE-associated PUK. SLE with evidence of systemic vasculitis has significantly higher mortality.<xref ref-type="bibr" rid="article-140253.r44">[44]</xref></p>
        <p>
<bold>Special&#x000a0;Circumstances</bold>
</p>
        <p>Some patients with PUK require complex therapeutic approaches. These special circumstances are explained below.</p>
        <p>
<bold>Pediatric patients</bold>
</p>
        <p>MTX is considered a first-line immunosuppressant&#x000a0;for pediatric patients with PUK related to systemic disease. Cyclosporine&#x000a0;may be considered if MTX does not elicit a response. These agents should be avoided during pregnancy due to their potential teratogenicity. Oral steroids&#x000a0;may be used cautiously in children.</p>
        <p>
<bold>Patients on existing immunosuppression regimens</bold>
</p>
        <p>Infectious etiologies should be excluded before planning further PUK treatment in these individuals.&#x000a0;Evaluation for potential acute exacerbations of systemic disease should be initiated. A change in systemic disease status may prompt the medical team to implement a step-up or maintenance strategy.&#x000a0;Rheumatologists or immunologists evaluate the clinical response to immunosuppression, typically 6 months&#x000a0;from treatment initiation.</p>
        <p>
<bold>Mooren Ulcer</bold>
</p>
        <p>The diagnosis of Mooren ulcer is one of exclusion. The management strategy is a stepladder approach, with topical corticosteroids and cyclosporine (0.05%&#x000a0;to 2%) initially, then progressing to limbal conjunctival resection or excision, systemic immunosuppressants, such as oral corticosteroids, MTX, cyclophosphamide, and cyclosporine, and surgery, including astigmatism treatment. Surgery alone is unlikely to be curative due to the underlying autoimmune pathophysiology.<xref ref-type="bibr" rid="article-140253.r45">[45]</xref></p>
        <p>An association between hepatitis C infection and a Mooren ulcer clinical phenotype has been reported.<xref ref-type="bibr" rid="article-140253.r46">[46]</xref>&#x000a0;Therapy with interferon-&#x003b1;2b&#x000a0;is effective in treating&#x000a0;corneal ulceration&#x000a0;while inducing hepatic disease remission.<xref ref-type="bibr" rid="article-140253.r47">[47]</xref>&#x000a0;</p>
        <p>
<bold>Surgical Management</bold>
</p>
        <p>Surgery has&#x000a0;a higher risk of PUK recurrence and graft melts.&#x000a0;Thus, this approach should be delayed until adequate control of inflammation is achieved.<xref ref-type="bibr" rid="article-140253.r48">[48]</xref>&#x000a0;Graft survival is less than 50% at&#x000a0;6 months;&#x000a0;hence,&#x000a0;multiple grafts are required in many patients.&#x000a0;Emergency surgical management depends on the indication. A therapeutic indication would be ulcers extending circumferentially, inducing corneal melt.&#x000a0;A tectonic indication is&#x000a0;a perforation or descemetocele.&#x000a0;An optical indication&#x000a0;is visual rehabilitation.</p>
        <p>The corneal defect size determines the appropriate surgical technique. Multilayered amniotic membrane transplant and conjunctival resection, recession, or flaps&#x000a0;may be options in areas&#x000a0;with corneal thinning.<xref ref-type="bibr" rid="article-140253.r49">[49]</xref> Conjunctival resection removes the tissue supplying inflammatory mediators to the cornea. Lamellar patch grafts reduce graft rejection risk compared with a full-thickness patch or tectonic grafts.<xref ref-type="bibr" rid="article-140253.r50">[50]</xref><xref ref-type="bibr" rid="article-140253.r51">[51]</xref>&#x000a0;Corneal glue, ie, cyanoacrylate, with a bandage contact lens&#x000a0;may be deployed if the perforation is less than 3 mm in diameter.<xref ref-type="bibr" rid="article-140253.r52">[52]</xref></p>
      </sec>
      <sec id="article-140253.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of PUK includes all conditions that can present as peripheral corneal thinning or opacification, as described in Table 2. In marginal keratitis, a clear cornea is often visible between the limbus and the infiltrates. Peripheral corneal degenerations are noninflammatory, have intact epithelium, and&#x000a0;lack infiltrates.</p>
        <table-wrap id="article-140253.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2. Differential Diagnosis&#x000a0;of&#x000a0;Peripheral Ulcerative Keratitis</title>
          </caption>
          <table style="margin-left: auto; margin-right: auto; height: 262px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 219.884px; text-align: left;" rowspan="1" colspan="1">
<bold>Inflammatory</bold>
</td>
                <td style="width: 205.402px; text-align: left;" rowspan="1" colspan="1">
<bold>Noninflammatory</bold>
</td>
              </tr>
              <tr>
                <td style="width: 219.884px; text-align: left;" rowspan="1" colspan="1">
<p>Staphylococcal marginal keratitis</p>
<p>Phlyctenulosis</p>
<p>Vernal keratoconjunctivitis</p>
<p>Infectious&#x000a0;keratitis</p>
<p>Exposure keratitis</p>
<p>Trichiasis</p>
<p>Lid malpositions</p>
</td>
                <td style="width: 205.402px; text-align: left;" rowspan="1" colspan="1">
<p>Terrien marginal degeneration</p>
<p>Pellucid marginal degeneration</p>
<p>Senile furrows</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Ruling out&#x000a0;clinical mimics is&#x000a0;crucial&#x000a0;when determining the appropriate management. The following conditions should be considered:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mooren ulcer: A chronic, progressive, and idiopathic condition that leads to peripheral corneal ulceration and thinning similar to PUK but without systemic involvement.</p>
          </list-item>
          <list-item>
            <p>Infectious keratitis: This condition encompasses bacterial, fungal, viral, and<italic toggle="yes"> Acanthamoeba</italic> infections. Cultures and corneal scrapings are vital to the evaluation process, as their management approaches differ significantly.</p>
          </list-item>
          <list-item>
            <p>Terrien marginal degeneration: Terrien degeneration is a noninflammatory thinning of the peripheral cornea. Unlike PUK, this condition usually lacks the overlying epithelial defect and inflammatory response.</p>
          </list-item>
          <list-item>
            <p>Scleritis-associated keratitis: Scleritis can involve the cornea in severe cases. This condition must be distinguished from primary corneal diseases like PUK, especially when associated with systemic vasculitis.</p>
          </list-item>
          <list-item>
            <p>Neurotrophic keratopathy: This condition is characterized by&#x000a0;corneal ulceration due to reduced corneal sensation.&#x000a0;Neurotrophic&#x000a0;keratopathy can mimic peripheral ulceration, but it usually occurs in different regions of the cornea and lacks the autoimmune or systemic inflammatory signs of PUK.<xref ref-type="bibr" rid="article-140253.r53">[53]</xref></p>
          </list-item>
          <list-item>
            <p>Ocular surface disease: Conditions such as severe dry eye syndrome or limbal stem cell deficiency can lead to peripheral corneal thinning without the acute inflammatory component seen in PUK.<xref ref-type="bibr" rid="article-140253.r54">[54]</xref></p>
          </list-item>
          <list-item>
            <p>Rosacea keratitis: Peripheral corneal involvement can occur in ocular rosacea, often presenting with punctate epithelial erosions, marginal infiltrates, or peripheral corneal thinning.<xref ref-type="bibr" rid="article-140253.r55">[55]</xref><xref ref-type="bibr" rid="article-140253.r56">[56]</xref></p>
          </list-item>
          <list-item>
            <p>Rheumatoid arthritis-associated keratitis: Systemic autoimmune diseases, like rheumatoid arthritis, are strongly associated with PUK. Primary corneal disease&#x000a0;must be distinguished from secondary keratitis due to systemic conditions.</p>
          </list-item>
          <list-item>
            <p>Limbal vernal keratoconjunctivitis: This disorder&#x000a0;can cause peripheral corneal ulcers, known as Shield ulcers, which tend to be large and oval, often involving the central cornea.<xref ref-type="bibr" rid="article-140253.r57">[57]</xref></p>
          </list-item>
          <list-item>
            <p>Corneal degeneration: Peripheral corneal degenerative conditions such as pellucid marginal and furrow degeneration may present with peripheral corneal thinning but lack PUK's ulcerative and inflammatory nature.<xref ref-type="bibr" rid="article-140253.r58">[58]</xref></p>
          </list-item>
          <list-item>
            <p>Relapsing polychondritis: A rare autoimmune condition affecting cartilage, relapsing polychondritis can cause peripheral corneal ulceration and thinning, mimicking PUK in patients with multisystem involvement.<xref ref-type="bibr" rid="article-140253.r59">[59]</xref></p>
          </list-item>
          <list-item>
            <p>Stevens-Johnson syndrome and toxic epidermal necrolysis: These conditions&#x000a0;may present with peripheral corneal ulceration and scarring&#x000a0;resulting from ocular surface damage, especially in severe cases.<xref ref-type="bibr" rid="article-140253.r60">[60]</xref></p>
          </list-item>
          <list-item>
            <p>Limbal stem cell deficiency: This condition&#x000a0;can lead to peripheral corneal thinning and ulcers due to failure of corneal epithelial regeneration. However,&#x000a0;limbal stem&#x000a0;cell&#x000a0;deficiency generally presents with more chronic, diffuse corneal surface changes.<xref ref-type="bibr" rid="article-140253.r61">[61]</xref></p>
          </list-item>
          <list-item>
            <p>Granulomatosis with polyangiitis: This systemic vasculitis can lead to peripheral corneal ulceration and should be considered in cases of PUK with systemic&#x000a0;manifestations like&#x000a0;sinusitis&#x000a0;and lung involvement.<xref ref-type="bibr" rid="article-140253.r62">[62]</xref></p>
          </list-item>
          <list-item>
            <p>Systemic lupus erythematosus: SLE can cause peripheral corneal involvement similar to PUK, particularly in active systemic disease. Differentiation is critical for systemic management.<xref ref-type="bibr" rid="article-140253.r63">[63]</xref></p>
          </list-item>
          <list-item>
            <p>Sarcoidosis: This condition&#x000a0;can involve the eye, including the cornea, leading to keratitis or corneal thinning that mimics PUK, particularly in cases with systemic granulomatous involvement.<xref ref-type="bibr" rid="article-140253.r64">[64]</xref></p>
          </list-item>
        </list>
        <p>Recognizing the broad spectrum of conditions that can mimic PUK&#x000a0;is essential for accurate diagnosis and treatment. Each condition requires a different therapeutic approach, particularly&#x000a0;in the presence of systemic involvement. A comprehensive history, clinical evaluation, and diagnostic tests, such as blood work and imaging, are critical to differentiate PUK from similar corneal conditions. Proper clinical, microbiological, and, sometimes, histopathological examinations&#x000a0;are essential to differentiate between causes of PUK. Early and accurate diagnosis is critical for appropriate treatment and prevention of complications such as corneal perforation.</p>
      </sec>
      <sec id="article-140253.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>
<bold>Key Historical Studies</bold>
</p>
        <p>Research has shown that systemic immunosuppressive therapy, eg, methotrexate or azathioprine administration, improves outcomes in autoimmune-related PUK by reducing recurrence rates. Meanwhile, numerous studies have demonstrated the effectiveness of corticosteroids in controlling local inflammation and preventing corneal perforation in noninfectious PUK.<xref ref-type="bibr" rid="article-140253.r65">[65]</xref></p>
        <p>
<bold>Trials Investigating Biologics</bold>
</p>
        <p>Ongoing trials explore the use of&#x000a0;antitumor necrosis factor-&#x003b1;&#x000a0;agents like infliximab and adalimumab in cases of rheumatoid arthritis-associated PUK. Trials with drugs such as tocilizumab, which blocks the interleukin-6 receptor, are being conducted to determine their ability to control severe, refractory cases of autoimmune PUK.</p>
        <p>
<bold>Radiation Therapy in Ocular Inflammatory Diseases</bold>
</p>
        <p>The efficacy of low-dose radiation therapy for managing severe, sight-threatening ocular inflammation has been investigated.&#x000a0;Research has shown mixed results but is&#x000a0;worth exploring in chronic, unresponsive cases.<xref ref-type="bibr" rid="article-140253.r66">[66]</xref></p>
        <p>
<bold>Corneal Grafting and Limbal Stem Cell Research</bold>
</p>
        <p>Newer techniques in corneal grafting and advancements in limbal stem cell transplantation for long-term vision restoration in patients with PUK have been gaining attention.<xref ref-type="bibr" rid="article-140253.r67">[67]</xref></p>
        <p>The evidence from these trials helps guide treatment decisions, particularly in severe or refractory cases of PUK where conventional therapies may not be effective. These studies also offer promising avenues for future treatment strategies, improving patient outcomes and minimizing complications.</p>
      </sec>
      <sec id="article-140253.s12" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>Treatment planning for PUK involves an interprofessional approach to managing the local corneal pathology and any underlying systemic autoimmune conditions. The essential components include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Local management
<list list-type="bullet"><list-item><p>Initial treatment involves topical corticosteroids or immunosuppressive agents to control inflammation.</p></list-item><list-item><p>Antibiotic drops may be necessary to prevent or treat secondary infections.</p></list-item><list-item><p>Surgical interventions, such as tissue glue or keratoplasty, may be needed to address corneal thinning or perforation.<xref ref-type="bibr" rid="article-140253.r68">[68]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Systemic immunosuppression
<list list-type="bullet"><list-item><p>The choice of immunosuppressive therapy (eg, corticosteroids, methotrexate, and azathioprine) depends on the severity of the systemic autoimmune disease.</p></list-item><list-item><p>Long-term maintenance therapy may be necessary to prevent recurrence.<xref ref-type="bibr" rid="article-140253.r69">[69]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Collaboration with rheumatologists
<list list-type="bullet"><list-item><p>Collaboration with rheumatologists is crucial for systemic disease management since PUK is often associated with autoimmune diseases.</p></list-item><list-item><p>Adjusting systemic immunosuppressive therapy is often required to control both ocular and systemic symptoms.<xref ref-type="bibr" rid="article-140253.r70">[70]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Regular monitoring
<list list-type="bullet"><list-item><p>Ongoing monitoring through regular ophthalmic exams and systemic workups ensures local and systemic control, helping to prevent complications like corneal perforation.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>This plan allows for comprehensive management of ocular and systemic PUK involvement.</p>
      </sec>
      <sec id="article-140253.s13" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>Toxicity and adverse&#x000a0;events from managing PUK are primarily related to the systemic immunosuppressive therapies used to control the underlying autoimmune disease.&#x000a0;An outline of potential toxicities and their management is provided below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Corticosteroids
<list list-type="bullet"><list-item><p>Toxicity: Prolonged use can lead to cataract formation, glaucoma, and systemic effects such as hyperglycemia, hypertension, osteoporosis, and adrenal suppression.</p></list-item><list-item><p>Management: Regular intraocular pressure checks, monitoring blood glucose levels, and tapering steroids when appropriate are typical strategies.&#x000a0;Using topical steroids with the lowest effective dose can mitigate systemic side effects.<xref ref-type="bibr" rid="article-140253.r71">[71]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Methotrexate
<list list-type="bullet"><list-item><p>Toxicity: Liver toxicity, bone marrow suppression, and lung toxicity are potential concerns with long-term use of this drug.</p></list-item><list-item><p>Management: Regular blood tests&#x000a0;can help&#x000a0;monitor liver function and complete blood counts. Folic acid supplementation is often used to reduce toxicity. Pulmonary function tests may also be required.<xref ref-type="bibr" rid="article-140253.r72">[72]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Cyclophosphamide
<list list-type="bullet"><list-item><p>Toxicity: Hemorrhagic cystitis, bone marrow suppression, increased risk of infections, and secondary malignancies are risks.</p></list-item><list-item><p>Management:&#x000a0;The&#x000a0;standard&#x000a0;approach includes hydration, using mesna to prevent bladder toxicity, regular blood work, and infection prophylaxis where appropriate.<xref ref-type="bibr" rid="article-140253.r73">[73]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Azathioprine
<list list-type="bullet"><list-item><p>Toxicity:&#x000a0;Adverse effects include bone marrow suppression, liver toxicity, and increased infection risk.</p></list-item><list-item><p>Management: The usual strategies include&#x000a0;regular blood counts, liver function tests, and dose adjustments based on tolerance and side effects.<xref ref-type="bibr" rid="article-140253.r74">[74]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Biologic agents,&#x000a0;including&#x000a0;tumor necrosis factor&#x000a0;inhibitors
<list list-type="bullet"><list-item><p>Toxicity:&#x000a0;These agents increase the risk of infections, including tuberculosis, and potential infusion reactions.</p></list-item><list-item><p>Management: The standard approach includes&#x000a0;screening for tuberculosis before initiating therapy, monitoring for signs of infection, and managing infusion reactions with premedication if necessary.<xref ref-type="bibr" rid="article-140253.r75">[75]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>In summary, toxicity management involves regular monitoring through laboratory work, dose adjustments, and appropriate prophylactic measures to mitigate the risks of long-term immunosuppressive therapy.</p>
      </sec>
      <sec id="article-140253.s14" sec-type="Staging">
        <title>Staging</title>
        <p>PUK is not typically classified into formal stages. However, this condition can be categorized based on the severity of corneal involvement and systemic disease activity.&#x000a0;Below is a practical way of staging&#x000a0;this condition:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild stage: This stage involves localized peripheral corneal ulceration, with the lesion's extent limited to less than 2 to 3 clock hours. The ulceration does not penetrate deeply into the stroma, and signs of impending perforation are absent. The patient may present with mild-to-moderate symptoms, including redness, irritation, and tearing.</p>
          </list-item>
          <list-item>
            <p>Moderate stage: Corneal ulceration becomes more extensive, involving 3&#x000a0;to 5 clock hours of the peripheral cornea. Stromal thinning is moderate,&#x000a0;but the patient may exhibit significant symptoms, including pain, photophobia, and decreased vision. The risk of corneal perforation begins to increase, and signs of&#x000a0;greater systemic inflammatory activity or associated autoimmune disease are evident.</p>
          </list-item>
          <list-item>
            <p>Severe stage: This stage is characterized by extensive corneal damage, usually with more than 5 clock hours or circumferential involvement. Corneal thinning is significant, and&#x000a0;the risk of&#x000a0;perforation is high. Patients are often in severe pain,&#x000a0;with the risk of visual loss considerably elevated.&#x000a0;This stage is likely to require surgical intervention, eg, tissue gluing or corneal transplant. Systemic disease activity may also be at its peak,&#x000a0;potentially warranting aggressive immunosuppressive therapy.<xref ref-type="bibr" rid="article-140253.r76">[76]</xref></p>
          </list-item>
          <list-item>
            <p>Perforated&#x000a0;or complicated stage: Corneal perforation occurs if the disease is uncontrolled or progresses rapidly, requiring emergency surgical management. This stage may also involve secondary complications such as glaucoma, secondary infections, or vision loss.</p>
          </list-item>
        </list>
        <p>Systemic staging may also be considered based on the activity of the associated autoimmune or systemic disease, such as rheumatoid arthritis or&#x000a0;GPA.</p>
      </sec>
      <sec id="article-140253.s15" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>PUK cases&#x000a0;with systemic associations and late disease presentation are harder to manage and generally have higher morbidity and mortality. The combination of scleritis&#x000a0;and PUK often bears&#x000a0;poor ocular and systemic prognosis.</p>
        <p>Corneal perforation results in a poor visual outcome despite response to treatment, with 65% of patients having a final vision of counting fingers or worse.&#x000a0;Corneal perforation is associated with 1-year mortality rates of 24% for unilateral cases and 50% for bilateral cases.</p>
        <p>The prognosis of PUK depends largely on the underlying cause, the promptness of diagnosis, and the adequacy of treatment.&#x000a0;Below are some key points regarding the prognosis.</p>
        <list list-type="bullet">
          <list-item>
            <p>Early diagnosis and treatment: The prognosis for preserving vision is generally better if PUK is diagnosed early and treated appropriately, especially&#x000a0;if&#x000a0;the underlying systemic disease is&#x000a0;controlled. Delayed treatment can lead to more severe complications and visual loss.<xref ref-type="bibr" rid="article-140253.r77">[77]</xref></p>
          </list-item>
          <list-item>
            <p>Risk of recurrence: PUK can recur, especially if associated with systemic autoimmunity. Continuous management of the underlying disease is crucial to prevent recurrence.</p>
          </list-item>
          <list-item>
            <p>Severity of disease: The prognosis is poorer in cases complicated with corneal perforation or extensive scleral involvement. Surgical intervention like corneal transplantation or conjunctival resection may be necessary but carries risks of graft failure and further damage.<xref ref-type="bibr" rid="article-140253.r78">[78]</xref></p>
          </list-item>
          <list-item>
            <p>Systemic involvement: Patients with associated systemic conditions such as vasculitis or collagen vascular diseases may face a more guarded prognosis, as these conditions can cause ongoing ocular and systemic issues that complicate recovery and management.<xref ref-type="bibr" rid="article-140253.r79">[79]</xref></p>
          </list-item>
          <list-item>
            <p>Visual prognosis: The extent of corneal involvement significantly influences visual outcomes. Mild cases with peripheral ulceration that do not affect the central visual axis often have a better visual prognosis, while central involvement can lead to permanent visual impairment.</p>
          </list-item>
          <list-item>
            <p>Risk of corneal perforation:&#x000a0;The risk of corneal perforation increases&#x000a0;when ulceration progresses rapidly, worsening the&#x000a0;prognosis. Corneal perforation may necessitate emergency surgical intervention, such as corneal gluing, patch grafts, or full-thickness corneal transplantation.<xref ref-type="bibr" rid="article-140253.r80">[80]</xref></p>
          </list-item>
          <list-item>
            <p>Impact of immunosuppressive therapy: The prognosis improves with systemic or corticosteroid therapy, especially in autoimmune-related PUK. Appropriate systemic treatment can prevent further disease progression and avoid complications such as perforation or loss of the eye&#x000a0;(phthisis bulbi).</p>
          </list-item>
          <list-item>
            <p>Need for ongoing monitoring: Due to the chronic and relapsing nature of PUK, patients require long-term follow-up to monitor for recurrence or complications. Lifelong management of any associated systemic disease is critical to maintaining eye health and preventing future episodes of PUK.</p>
          </list-item>
          <list-item>
            <p>Surgical outcomes: In severe cases requiring procedures like corneal transplantation, the success rate of surgery&#x000a0;may be influenced by the activity of the underlying systemic disease. The risk of graft rejection or failure is higher if inflammation is not well-controlled.</p>
          </list-item>
          <list-item>
            <p>Quality of life: PUK, especially in advanced or recurrent cases, can significantly affect the patient's quality of life due to chronic pain, frequent need for medical appointments, and visual impairment. Psychological and social support may be necessary for patients with severe disease.<xref ref-type="bibr" rid="article-140253.r81">[81]</xref></p>
          </list-item>
          <list-item>
            <p>Long-term management: For patients with autoimmune diseases, the long-term prognosis depends not&#x000a0;only on ophthalmologic treatment but also on controlling the systemic condition. Ongoing collaboration between ophthalmologists, rheumatologists, and internists is essential to provide comprehensive care and improve long-term outcomes.</p>
          </list-item>
          <list-item>
            <p>Potential for severe complications:&#x000a0;PUK can lead to serious complications if left untreated or inadequately managed, including severe scarring, secondary glaucoma, and even phthisis bulbi in extreme cases.<xref ref-type="bibr" rid="article-140253.r82">[82]</xref></p>
          </list-item>
        </list>
        <p>Effective interprofessional management involving specialists such as ophthalmologists and rheumatologists is essential to improving the long-term prognosis of PUK.</p>
      </sec>
      <sec id="article-140253.s16" sec-type="Complications">
        <title>Complications</title>
        <p>Below&#x000a0;are the possible complications of PUK.</p>
        <list list-type="bullet">
          <list-item>
            <p>Corneal perforation:&#x000a0;Severe inflammation can lead to corneal thinning and perforation, requiring urgent surgical intervention, such as corneal patch grafts or amniotic membrane transplantation.<xref ref-type="bibr" rid="article-140253.r83">[83]</xref>&#x000a0;This condition&#x000a0;is the most serious ocular complication of PUK and&#x000a0;may involve&#x000a0;both eyes.&#x000a0;Corneal&#x000a0;perforation has a detrimental effect on final vision and can result in visual loss. The risk of mortality increases in patients with PUK due to systemic associations, particularly when perforation occurs.</p>
          </list-item>
          <list-item>
            <p>Vision loss: Chronic or untreated PUK&#x000a0;may result in significant vision loss due to scarring, irregular astigmatism, or corneal opacity.<xref ref-type="bibr" rid="article-140253.r84">[84]</xref></p>
          </list-item>
          <list-item>
            <p>Secondary&#x000a0;infections: The ulcerative nature of PUK makes the cornea more susceptible to secondary bacterial, fungal, or viral infections, complicating management and delaying healing.<xref ref-type="bibr" rid="article-140253.r85">[85]</xref></p>
          </list-item>
          <list-item>
            <p>Recurrence of autoimmune disease: PUK is often associated with systemic autoimmune conditions. Systemic or ocular disease may recur despite treatment, requiring ongoing immunosuppressive therapy.</p>
          </list-item>
          <list-item>
            <p>Scleral involvement: Inflammation can extend from the cornea to the sclera, leading to scleritis, which can cause intense pain, further tissue damage, and pose a significant risk to the eye's structural integrity.</p>
          </list-item>
          <list-item>
            <p>Corneal melting: Rapid stromal degradation and "melting" of the corneal tissue may occur, requiring prompt treatment to prevent perforation or further complications.<xref ref-type="bibr" rid="article-140253.r86">[86]</xref></p>
          </list-item>
          <list-item>
            <p>Glaucoma: Secondary glaucoma can arise from chronic inflammation or corticosteroid treatment.&#x000a0;Glaucoma may increase intraocular pressure, potentially damaging the&#x000a0;optic nerve.<xref ref-type="bibr" rid="article-140253.r87">[87]</xref></p>
          </list-item>
          <list-item>
            <p>Anterior uveitis: Inflammation in the front of the eye,&#x000a0;ie, iritis or anterior uveitis, is commonly associated with PUK and contributes to pain, light sensitivity, and visual impairment.<xref ref-type="bibr" rid="article-140253.r88">[88]</xref></p>
          </list-item>
          <list-item>
            <p>Cataract formation: Long-term corticosteroid use, often needed for autoimmune conditions associated with PUK, can accelerate the development of cataracts, leading to cloudy vision.<xref ref-type="bibr" rid="article-140253.r89">[89]</xref></p>
          </list-item>
          <list-item>
            <p>Symblepharon formation: Severe ocular surface disease and chronic inflammation may&#x000a0;induce the formation of adhesions between the eyelid and eyeball, also known as symblepharon, which can impair eye movement and eyelid function.<xref ref-type="bibr" rid="article-140253.r90">[90]</xref></p>
          </list-item>
          <list-item>
            <p>Corneal neovascularization: Chronic inflammation may lead to the growth of abnormal blood vessels into the cornea, which can cause further vision impairment and reduce corneal transparency.<xref ref-type="bibr" rid="article-140253.r91">[91]</xref></p>
          </list-item>
          <list-item>
            <p>Steroid-induced complications: Potential adverse effects&#x000a0;of prolonged corticosteroid therapy include delayed wound healing, cataracts, and increased susceptibility to infections.<xref ref-type="bibr" rid="article-140253.r92">[92]</xref></p>
          </list-item>
          <list-item>
            <p>Chronic pain: Persistent inflammation and damage to the ocular surface can&#x000a0;produce chronic pain, which can affect&#x000a0;a patient&#x02019;s quality of life.</p>
          </list-item>
          <list-item>
            <p>Endophthalmitis: Infection may penetrate the deeper eye structures in rare and severe cases, leading to endophthalmitis, a sight-threatening condition requiring urgent medical attention.<xref ref-type="bibr" rid="article-140253.r93">[93]</xref></p>
          </list-item>
        </list>
        <p>Prevention of these complications&#x000a0;requires prompt diagnosis, aggressive treatment, and&#x000a0;an interprofessional approach to management.</p>
      </sec>
      <sec id="article-140253.s17" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Postoperative and rehabilitation care for PUK&#x000a0;should include the following measures:</p>
        <list list-type="bullet">
          <list-item>
            <p>Monitoring for graft rejection or failure: If a corneal graft is performed, close postoperative monitoring is necessary to detect signs of graft rejection or failure early. Frequent follow-ups with corneal specialists are recommended.</p>
          </list-item>
          <list-item>
            <p>Topical and systemic medications: Topical steroids and antibiotics should be continued to&#x000a0;control inflammation and prevent infection, respectively. Depending on the underlying cause, immunosuppressive therapy may also be required in the long term.<xref ref-type="bibr" rid="article-140253.r94">[94]</xref></p>
          </list-item>
          <list-item>
            <p>Visual rehabilitation: After the acute phase is controlled, rehabilitation may involve using corrective lenses. Additional surgical interventions may be required to restore vision in some individuals.<xref ref-type="bibr" rid="article-140253.r95">[95]</xref></p>
          </list-item>
          <list-item>
            <p>Patient education: Educating the patient about medication adherence and recognition of the&#x000a0;symptoms of recurrence or complications is crucial to long-term management and visual outcomes.<xref ref-type="bibr" rid="article-140253.r96">[96]</xref></p>
          </list-item>
        </list>
        <p>Good&#x000a0;postoperative and rehabilitation care improves long-term corneal health and vision in patients with PUK, with reduced risk of complications or recurrence.</p>
      </sec>
      <sec id="article-140253.s18" sec-type="Consultations">
        <title>Consultations</title>
        <p>Specialists who must be involved in&#x000a0;PUK management should include the following healthcare professionals:</p>
        <list list-type="bullet">
          <list-item>
            <p>Rheumatologist: Essential for managing systemic autoimmune conditions underlying&#x000a0;PUK to determine and adjust systemic therapy and prevent further corneal damage.<xref ref-type="bibr" rid="article-140253.r97">[97]</xref></p>
          </list-item>
          <list-item>
            <p>Infectious disease specialist: Should be consulted if an infectious etiology is suspected, particularly in cases with&#x000a0;systemic&#x000a0;presentations like syphilis, tuberculosis, and some viral illnesses.<xref ref-type="bibr" rid="article-140253.r98">[98]</xref></p>
          </list-item>
          <list-item>
            <p>Corneal specialist: Early involvement of an ophthalmologist specializing in corneal diseases is crucial for assessing the extent of damage and considering surgical interventions, such as corneal transplantation, if necessary.<xref ref-type="bibr" rid="article-140253.r99">[99]</xref></p>
          </list-item>
          <list-item>
            <p>Immunologist: Consider a consultation to evaluate the patient&#x02019;s immune status and provide recommendations on immunosuppressive therapies when conventional treatment fails to control the autoimmune aspects of PUK.<xref ref-type="bibr" rid="article-140253.r100">[100]</xref></p>
          </list-item>
        </list>
        <p>Interprofessional&#x000a0;consultations ensure comprehensive care for managing PUK's ocular and systemic aspects.</p>
      </sec>
      <sec id="article-140253.s19" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>PUK&#x000a0;is an ophthalmic emergency, as&#x000a0;patients are&#x000a0;at risk of corneal perforation and blindness.<xref ref-type="bibr" rid="article-140253.r101">[101]</xref>&#x000a0;An interprofessional approach to investigation and management is required, involving collaboration between several&#x000a0;specialists. The long-term need for immunosuppression&#x000a0;may&#x000a0;produce&#x000a0;adverse side effects. Relapses can occur.&#x000a0;A clear management plan and good patient communication are&#x000a0;necessary for safe outcomes.</p>
        <p>Deterrence measures and concepts to emphasize during patient education should include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Importance of early detection:&#x000a0;Educate patients with autoimmune diseases about the early signs of PUK, such as eye redness, pain, and vision changes, to ensure prompt medical attention.<xref ref-type="bibr" rid="article-140253.r102">[102]</xref></p>
          </list-item>
          <list-item>
            <p>Systemic disease management:&#x000a0;Emphasize the need for proper control of underlying systemic conditions through regular follow-up with rheumatologists to reduce the risk of ocular complications like PUK.<xref ref-type="bibr" rid="article-140253.r103">[103]</xref></p>
          </list-item>
          <list-item>
            <p>Compliance with treatment:&#x000a0;Stress the importance of adherence to prescribed immunosuppressive or corticosteroid therapy to prevent disease progression and avoid corneal perforation.<xref ref-type="bibr" rid="article-140253.r104">[104]</xref></p>
          </list-item>
          <list-item>
            <p>Regular eye examinations:&#x000a0;Patients with known systemic diseases should undergo regular ophthalmologic evaluations to detect early signs of corneal involvement before symptoms worsen.</p>
          </list-item>
        </list>
        <p>Providing clear and proactive education can help patients&#x000a0;avoid severe outcomes and improve their long-term eye health.</p>
      </sec>
      <sec id="article-140253.s20" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>
<bold>Pearls</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Early diagnosis is crucial for preventing corneal perforation and permanent vision loss.</p>
          </list-item>
          <list-item>
            <p>Systemic associations, especially autoimmune conditions like rheumatoid arthritis, should always be considered when diagnosing and managing PUK.</p>
          </list-item>
          <list-item>
            <p>Interprofessional&#x000a0;care involving ophthalmology and rheumatology improves patient outcomes by addressing local and systemic factors.</p>
          </list-item>
        </list>
        <p>
<bold>Disposition</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients with severe PUK, especially if associated with systemic disease, require hospitalization or close outpatient follow-up for frequent monitoring and adjustment of therapy.</p>
          </list-item>
          <list-item>
            <p>Discharge planning should ensure patients have clear medication adherence and follow-up care instructions, particularly when systemic immunosuppressive therapy is involved.<xref ref-type="bibr" rid="article-140253.r105">[105]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Pitfalls</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Delayed initiation of appropriate immunosuppressive therapy can lead to rapid progression, corneal thinning, and perforation.</p>
          </list-item>
          <list-item>
            <p>Misdiagnosis as simple infectious keratitis can occur if systemic evaluation is not performed, potentially leading to ineffective treatment and complicated PUK.</p>
          </list-item>
        </list>
        <p>
<bold>Prevention</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Early screening and treatment of ocular inflammation can prevent progression to PUK in at-risk populations,&#x000a0;such as patients with autoimmune diseases.</p>
          </list-item>
          <list-item>
            <p>Appropriate patient education on recognizing early symptoms such as redness, pain, and vision changes can lead to timely treatment.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-140253.s21" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>PUK&#x000a0;can be a diagnostic challenge. Patients with this condition&#x000a0;may exhibit no systemic symptoms or signs that point to the underlying cause and require an interprofessional team consisting of an ophthalmologist, rheumatologist, dermatologist, internist, neurologist, pharmacist, nursing staff, and technicians. Significant visual loss&#x000a0;warrants coordination with the eye clinic liaison staff, and sight impairment registration will need to be undertaken. The etiology of PUK requires meticulous clinical investigation. Patient education should touch up on treatment compliance and the potential side effects of immunosuppressants, including corticosteroids.&#x000a0;During prolonged treatment and monitoring of disease activity, shared care with internists and rheumatologists can last for years after the initial diagnosis.&#x000a0;</p>
        <p>Enhancing healthcare team outcomes for PUK requires coordinated efforts and strategic approaches from an interprofessional team. The following&#x000a0;are key considerations:</p>
        <list list-type="bullet">
          <list-item>
            <p>Skills and strategy
<list list-type="bullet"><list-item><p>Diagnosis and assessment: Ophthalmologists and optometrists must accurately diagnose PUK through clinical examination, slit-lamp microscopy, and appropriate imaging or biopsy when needed.</p></list-item><list-item><p>Pharmacological management: Pharmacists and physicians collaborate on the appropriate selection and dosage of immunosuppressive agents, corticosteroids, and antibiotics.</p></list-item><list-item><p>Surgical interventions: Surgeons may need to address severe cases by performing a reparative procedure, such as corneal transplantation.</p></list-item><list-item><p>Ongoing monitoring: Nurses and advanced practitioners help with routine monitoring, ensuring patient adherence to treatment, and identifying early signs of complications.<xref ref-type="bibr" rid="article-140253.r106">[106]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Ethical and team responsibilities
<list list-type="bullet"><list-item><p>Patient-centered care: All team members should ensure that the patient is informed and involved in decision-making and that care plans respect the patient's preferences and values.</p></list-item><list-item><p>Interprofessional communication: Effective communication between the healthcare providers ensures timely treatment adjustments and coordinated care.</p></list-item><list-item><p>Interprofessional approach: Collaboration between ophthalmologists, rheumatologists, and, possibly, dermatologists ensures systemic causes of&#x000a0;PUK&#x000a0;are managed comprehensively.</p></list-item><list-item><p>Outcome evaluation: Regular assessment of patient progress, both in terms of clinical healing and quality of life, is essential to ensure that care remains optimal and evidence-based.<xref ref-type="bibr" rid="article-140253.r107">[107]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>These combined efforts result in enhanced patient outcomes, reduced complications, and better team performance in managing PUK.</p>
      </sec>
      <sec id="article-140253.s22">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140253&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140253">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/peripheral-ulcerative-keratitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=140253">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/140253/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=140253">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-140253.s23">
        <fig id="article-140253.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Peripheral Ulcerative Keratitis in&#x000a0;Rheumatoid Arthritis.&#x000a0;Note the signs of severe inflammation,&#x000a0;such as scleral and corneal&#x000a0;hyperemia and tearing, as well as corneal thinning, with the peripheral area appearing deformed and grayish. Contributed by Lanxing Fu, MD.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PUK1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-140253.s24">
        <title>References</title>
        <ref id="article-140253.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kate</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Systemic Immunosuppression in Cornea and Ocular Surface Disorders: A Ready Reckoner for Ophthalmologists.</article-title>
            <source>Semin Ophthalmol</source>
            <year>2022</year>
            <month>Apr</month>
            <day>03</day>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>330</fpage>
            <page-range>330-344</page-range>
            <pub-id pub-id-type="pmid">34423717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shekhar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Titiyal</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vajpayee</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Demographic profile, clinical features and outcome of peripheral ulcerative keratitis: a prospective study.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>99</volume>
            <issue>11</issue>
            <fpage>1503</fpage>
            <page-range>1503-8</page-range>
            <pub-id pub-id-type="pmid">25935428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kishore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Balakrishnan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lomi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vanathi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Peripheral ulcerative keratitis.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2021</year>
            <season>Nov-Dec</season>
            <volume>66</volume>
            <issue>6</issue>
            <fpage>977</fpage>
            <page-range>977-998</page-range>
            <pub-id pub-id-type="pmid">33657431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foo</surname>
                <given-names>VHX</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>ASY</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Case Report: Peripheral Ulcerative Keratitis in Systemic Solid Tumour Malignancies.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2022</year>
            <volume>9</volume>
            <fpage>907285</fpage>
            <pub-id pub-id-type="pmid">35712100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassanpour</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>H ElSheikh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arabi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>R Frank</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>M Elhusseiny</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>K Eleiwa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>R Djalilian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kheirkhah</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Peripheral Ulcerative Keratitis: A Review.</article-title>
            <source>J Ophthalmic Vis Res</source>
            <year>2022</year>
            <season>Apr-Jun</season>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>252</fpage>
            <page-range>252-275</page-range>
            <pub-id pub-id-type="pmid">35765625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thorne</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Scleritis and peripheral ulcerative keratitis.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>835</fpage>
            <page-range>835-54, vii</page-range>
            <pub-id pub-id-type="pmid">18037120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yagci</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Update on peripheral ulcerative keratitis.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2012</year>
            <volume>6</volume>
            <fpage>747</fpage>
            <page-range>747-54</page-range>
            <pub-id pub-id-type="pmid">22654502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Artaechevarria Artieda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Est&#x000e9;banez-Corrales</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Pernaute</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Alejandre-Alba</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Peripheral Ulcerative Keratitis in a Patient with Bilateral Scleritis: Medical and Surgical Management.</article-title>
            <source>Case Rep Ophthalmol</source>
            <year>2020</year>
            <season>Sep-Dec</season>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>500</fpage>
            <page-range>500-506</page-range>
            <pub-id pub-id-type="pmid">33173497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment.</article-title>
            <source>J Ophthalmol</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>7298026</fpage>
            <pub-id pub-id-type="pmid">28785483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tauber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sainz de la Maza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoang-Xuan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>An analysis of therapeutic decision making regarding immunosuppressive chemotherapy for peripheral ulcerative keratitis.</article-title>
            <source>Cornea</source>
            <year>1990</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-73</page-range>
            <pub-id pub-id-type="pmid">2297997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srinivasan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zegans</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Zelefsky</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kundu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lietman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Whitcher</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>ET</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics of Mooren's ulcer in South India.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2007</year>
            <month>May</month>
            <volume>91</volume>
            <issue>5</issue>
            <fpage>570</fpage>
            <page-range>570-5</page-range>
            <pub-id pub-id-type="pmid">17035269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watson</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Management of Mooren's ulceration.</article-title>
            <source>Eye (Lond)</source>
            <year>1997</year>
            <volume>11 ( Pt 3)</volume>
            <fpage>349</fpage>
            <page-range>349-56</page-range>
            <pub-id pub-id-type="pmid">9373475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKibbin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Morrell</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Incidence of corneal melting in association with systemic disease in the Yorkshire Region, 1995-7.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>83</volume>
            <issue>8</issue>
            <fpage>941</fpage>
            <page-range>941-3</page-range>
            <pub-id pub-id-type="pmid">10413698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sainz de la Maza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Jabbur</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Baltatzis</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ocular characteristics and disease associations in scleritis-associated peripheral keratopathy.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>120</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-9</page-range>
            <pub-id pub-id-type="pmid">11786052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Timlin</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Foot</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Koay</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Corneal perforation from peripheral ulcerative keratopathy in patients with rheumatoid arthritis: epidemiological findings of the British Ophthalmological Surveillance Unit.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>102</volume>
            <issue>9</issue>
            <fpage>1298</fpage>
            <page-range>1298-1302</page-range>
            <pub-id pub-id-type="pmid">29246891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sangwan</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Zafirakis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Mooren's ulcer: current concepts in management.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>1997</year>
            <month>Mar</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-17</page-range>
            <pub-id pub-id-type="pmid">9475006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooper</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Stroehla</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of autoimmune diseases.</article-title>
            <source>Autoimmun Rev</source>
            <year>2003</year>
            <month>May</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>119</fpage>
            <page-range>119-25</page-range>
            <pub-id pub-id-type="pmid">12848952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angum</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Prevalence of Autoimmune Disorders in Women: A Narrative Review.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>May</month>
            <day>13</day>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>e8094</fpage>
            <pub-id pub-id-type="pmid">32542149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vadasz</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Haj</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kessel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Toubi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Age-related autoimmunity.</article-title>
            <source>BMC Med</source>
            <year>2013</year>
            <month>Apr</month>
            <day>04</day>
            <volume>11</volume>
            <fpage>94</fpage>
            <pub-id pub-id-type="pmid">23556986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>FW</given-names>
              </name>
            </person-group>
            <article-title>The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention.</article-title>
            <source>Curr Opin Immunol</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>80</volume>
            <fpage>102266</fpage>
            <pub-id pub-id-type="pmid">36446151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robin</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Schanzlin</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Verity</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Barron</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Arffa</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Peripheral corneal disorders.</article-title>
            <source>Surv Ophthalmol</source>
            <year>1986</year>
            <season>Jul-Aug</season>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-36</page-range>
            <pub-id pub-id-type="pmid">3529467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Medeiros</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Santhiago</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Corneal nerves anatomy, function, injury and regeneration.</article-title>
            <source>Exp Eye Res</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>200</volume>
            <fpage>108243</fpage>
            <pub-id pub-id-type="pmid">32926895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Pels</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schurmans</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Vrensen</surname>
                <given-names>GF</given-names>
              </name>
            </person-group>
            <article-title>A new three-dimensional model of the organization of proteoglycans and collagen fibrils in the human corneal stroma.</article-title>
            <source>Exp Eye Res</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>493</fpage>
            <page-range>493-501</page-range>
            <pub-id pub-id-type="pmid">15106928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coelho</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Menezes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gon&#x000e7;alves</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Seara</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Peripheral Ulcerative Keratitis Associated with HCV-Related Cryoglobulinemia.</article-title>
            <source>Case Rep Ophthalmol Med</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>9461937</fpage>
            <pub-id pub-id-type="pmid">28785498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riley</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Harrall</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Cawston</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Hazleman</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Collagenase (MMP-1) and TIMP-1 in destructive corneal disease associated with rheumatoid arthritis.</article-title>
            <source>Eye (Lond)</source>
            <year>1995</year>
            <volume>9 ( Pt 6)</volume>
            <fpage>703</fpage>
            <page-range>703-18</page-range>
            <pub-id pub-id-type="pmid">8849537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Messmer</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Vasculitic peripheral ulcerative keratitis.</article-title>
            <source>Surv Ophthalmol</source>
            <year>1999</year>
            <season>Mar-Apr</season>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>379</fpage>
            <page-range>379-96</page-range>
            <pub-id pub-id-type="pmid">10340557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Jean</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Tsui</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Sheu</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>ZH</given-names>
              </name>
            </person-group>
            <article-title>Excavatolide B Attenuates Rheumatoid Arthritis through the Inhibition of Osteoclastogenesis.</article-title>
            <source>Mar Drugs</source>
            <year>2017</year>
            <month>Jan</month>
            <day>06</day>
            <volume>15</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">28067799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Byrd</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <chapter-title>Corneal Ulcer</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">30969511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayadas</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Tsokos</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Tsuboi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury.</article-title>
            <source>Circulation</source>
            <year>2009</year>
            <month>Nov</month>
            <day>17</day>
            <volume>120</volume>
            <issue>20</issue>
            <fpage>2012</fpage>
            <page-range>2012-24</page-range>
            <pub-id pub-id-type="pmid">19917895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ellenberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Azar</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Hallak</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Tobaigy</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Novel aspects of corneal angiogenic and lymphangiogenic privilege.</article-title>
            <source>Prog Retin Eye Res</source>
            <year>2010</year>
            <month>May</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>208</fpage>
            <page-range>208-48</page-range>
            <pub-id pub-id-type="pmid">20100589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Hashmi</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Conjunctivitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">31082078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r32">
          <label>32</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Schonberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stokkermans</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <chapter-title>Episcleritis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">30521217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Amador</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tormanen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ghiam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saghizadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arumugaswami</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kramerov</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ljubimov</surname>
                <given-names>AV</given-names>
              </name>
            </person-group>
            <article-title>Systemic diseases and the cornea.</article-title>
            <source>Exp Eye Res</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>204</volume>
            <fpage>108455</fpage>
            <pub-id pub-id-type="pmid">33485845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diaz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Natarelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rechdan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Botto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Forouzandeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Plaza</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kaffenberger</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous Manifestations of Rheumatoid Arthritis: Diagnosis and Treatment.</article-title>
            <source>J Pers Med</source>
            <year>2023</year>
            <month>Oct</month>
            <day>10</day>
            <volume>13</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">37888090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-R&#x000ed;os</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pecci-Lloret</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>O&#x000f1;ate-S&#x000e1;nchez</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Oral Manifestations of Systemic Lupus Erythematosus: A Systematic Review.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2022</year>
            <month>Sep</month>
            <day>21</day>
            <volume>19</volume>
            <issue>19</issue>
            <pub-id pub-id-type="pmid">36231212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gourley</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic testing and interpretation of tests for autoimmunity.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>125</volume>
            <issue>2 Suppl 2</issue>
            <fpage>S238</fpage>
            <page-range>S238-47</page-range>
            <pub-id pub-id-type="pmid">20061009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cabrera-Aguas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khoo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Infectious keratitis: A review.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>543</fpage>
            <page-range>543-562</page-range>
            <pub-id pub-id-type="pmid">35610943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e8;ve</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pacheco</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Durupt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jamilloux</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gerfaud-Valentin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Isaac</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boussel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Calender</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Androdias</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Valeyre</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>El Jammal</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Sarcoidosis: A Clinical Overview from Symptoms to Diagnosis.</article-title>
            <source>Cells</source>
            <year>2021</year>
            <month>Mar</month>
            <day>31</day>
            <volume>10</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">33807303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucchino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mastrogiuseppe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giovannetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bruscolini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marenco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lambiase</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Anterior Segment Optical Coherence Tomography for the Tailored Treatment of Mooren's Ulcer: A Case Report.</article-title>
            <source>J Clin Med</source>
            <year>2024</year>
            <month>Sep</month>
            <day>11</day>
            <volume>13</volume>
            <issue>18</issue>
            <pub-id pub-id-type="pmid">39336871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watanabe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yokokura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shirota</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Harigae</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Ulcerative keratitis in patients with rheumatoid arthritis in the modern biologic era: a series of eight cases and literature review.</article-title>
            <source>Int J Rheum Dis</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>225</fpage>
            <page-range>225-230</page-range>
            <pub-id pub-id-type="pmid">26179634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Messmer</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management.</article-title>
            <source>Cornea</source>
            <year>1995</year>
            <month>Jul</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>408</fpage>
            <page-range>408-17</page-range>
            <pub-id pub-id-type="pmid">7671613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ebrahimiadib</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Modjtahedi</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Roohipoor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anesi</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Successful Treatment Strategies in Granulomatosis With Polyangiitis-Associated Peripheral Ulcerative Keratitis.</article-title>
            <source>Cornea</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>35</volume>
            <issue>11</issue>
            <fpage>1459</fpage>
            <page-range>1459-1465</page-range>
            <pub-id pub-id-type="pmid">27362884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aizezi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Necrotizing scleritis and peripheral ulcerative keratitis associated with Wegener's granulomatosis.</article-title>
            <source>Ophthalmol Ther</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-111</page-range>
            <pub-id pub-id-type="pmid">25135810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Forstot</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression.</article-title>
            <source>Ophthalmology</source>
            <year>1984</year>
            <month>Oct</month>
            <volume>91</volume>
            <issue>10</issue>
            <fpage>1253</fpage>
            <page-range>1253-63</page-range>
            <pub-id pub-id-type="pmid">6514289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lal</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shivanagari</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Vazirani</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of conjunctival resection with cyanoacrylate glue application in preventing recurrences of Mooren's ulcer.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>100</volume>
            <issue>7</issue>
            <fpage>971</fpage>
            <page-range>971-975</page-range>
            <pub-id pub-id-type="pmid">26553919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gangaputra</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Newcomb</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Joffe</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Dreger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Begum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Artornsombudh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pujari</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Suhler</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Thorne</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Jabs</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Levy-Clarke</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Kempen</surname>
                <given-names>JH</given-names>
              </name>
              <collab>SITE Cohort Research Group</collab>
            </person-group>
            <article-title>Comparison Between Methotrexate and Mycophenolate Mofetil Monotherapy for the Control of Noninfectious Ocular Inflammatory Diseases.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>208</volume>
            <fpage>68</fpage>
            <page-range>68-75</page-range>
            <pub-id pub-id-type="pmid">31344346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matoba</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Wilhelmus</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Epstein-Barr viral stromal keratitis.</article-title>
            <source>Ophthalmology</source>
            <year>1986</year>
            <month>Jun</month>
            <volume>93</volume>
            <issue>6</issue>
            <fpage>746</fpage>
            <page-range>746-51</page-range>
            <pub-id pub-id-type="pmid">3737121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maeno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Naor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Rootman</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Three decades of corneal transplantation: indications and patient characteristics.</article-title>
            <source>Cornea</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-11</page-range>
            <pub-id pub-id-type="pmid">10632000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feder</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Krachmer</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Conjunctival resection for the treatment of the rheumatoid corneal ulceration.</article-title>
            <source>Ophthalmology</source>
            <year>1984</year>
            <month>Feb</month>
            <volume>91</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-5</page-range>
            <pub-id pub-id-type="pmid">6709325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sachdev</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Sutureless patch graft for sterile corneal melts.</article-title>
            <source>Cornea</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>29</volume>
            <issue>8</issue>
            <fpage>921</fpage>
            <page-range>921-3</page-range>
            <pub-id pub-id-type="pmid">20508506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bessant</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Dart</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Lamellar keratoplasty in the management of inflammatory corneal ulceration and perforation.</article-title>
            <source>Eye (Lond)</source>
            <year>1994</year>
            <volume>8 ( Pt 1)</volume>
            <fpage>22</fpage>
            <page-range>22-8</page-range>
            <pub-id pub-id-type="pmid">8013714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Qahtani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Asghar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Al-Taweel</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Jalaluddin</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Peripheral ulcerative keratitis: Our challenging experience.</article-title>
            <source>Saudi J Ophthalmol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>234</fpage>
            <page-range>234-8</page-range>
            <pub-id pub-id-type="pmid">25278804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r53">
          <label>53</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Feroze</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <chapter-title>Neurotrophic Keratitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">28613758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haagdorens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Acker</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Van Gerwen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>N&#x000ed; Dhubhghaill</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koppen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tassignon</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Zakaria</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Limbal Stem Cell Deficiency: Current Treatment Options and Emerging Therapies.</article-title>
            <source>Stem Cells Int</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>9798374</fpage>
            <pub-id pub-id-type="pmid">26788074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al Arfaj</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Al Zamil</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Spontaneous corneal perforation in ocular rosacea.</article-title>
            <source>Middle East Afr J Ophthalmol</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>186</fpage>
            <page-range>186-8</page-range>
            <pub-id pub-id-type="pmid">20616930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Christy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Narayana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moutappa</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Corneal Perforation Secondary to Rosacea Keratitis Managed with Excellent Visual Outcome.</article-title>
            <source>Nepal J Ophthalmol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>27</issue>
            <fpage>162</fpage>
            <page-range>162-167</page-range>
            <pub-id pub-id-type="pmid">35996914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r57">
          <label>57</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <chapter-title>Vernal Keratoconjunctivitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">35015458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r58">
          <label>58</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sahu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Raizada</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Pellucid Marginal Corneal Degeneration</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">32965985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borgia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giuffrida</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guarneri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cannav&#x000f2;</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Relapsing Polychondritis: An Updated Review.</article-title>
            <source>Biomedicines</source>
            <year>2018</year>
            <month>Aug</month>
            <day>02</day>
            <volume>6</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">30072598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r60">
          <label>60</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Labib</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Milroy</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <chapter-title>Toxic Epidermal Necrolysis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">34662044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Le</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>SX</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis of limbal stem cell deficiency.</article-title>
            <source>Ocul Surf</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-69</page-range>
            <pub-id pub-id-type="pmid">29113917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kubaisi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Abu Samra</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestations.</article-title>
            <source>Intractable Rare Dis Res</source>
            <year>2016</year>
            <month>May</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>61</fpage>
            <page-range>61-9</page-range>
            <pub-id pub-id-type="pmid">27195187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r63">
          <label>63</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Justiz Vaillant</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Varacallo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Systemic Lupus Erythematosus</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">30571026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r64">
          <label>64</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Simakurthy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Ocular Sarcoidosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">35593845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elsgaard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Danielsen</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Thyssen</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Deleuran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vestergaard</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Drug survival of systemic immunosuppressive treatments for atopic dermatitis in a long-term pediatric cohort.</article-title>
            <source>Int J Womens Dermatol</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>5Part B</issue>
            <fpage>708</fpage>
            <page-range>708-715</page-range>
            <pub-id pub-id-type="pmid">35028369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nuzzi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Trossarello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bartoncini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mantovani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ricardi</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Ocular Complications After Radiation Therapy: An Observational Study.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2020</year>
            <volume>14</volume>
            <fpage>3153</fpage>
            <page-range>3153-3166</page-range>
            <pub-id pub-id-type="pmid">33116366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elhusseiny</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Soleimani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eleiwa</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>ElSheikh</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Naderan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yazdanpanah</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rosenblatt</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Djalilian</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Current and Emerging Therapies for Limbal Stem Cell Deficiency.</article-title>
            <source>Stem Cells Transl Med</source>
            <year>2022</year>
            <month>Mar</month>
            <day>31</day>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>259</fpage>
            <page-range>259-268</page-range>
            <pub-id pub-id-type="pmid">35303110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suwan-Apichon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Reyes</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Herretes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vedula</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Chuck</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Topical corticosteroids as adjunctive therapy for bacterial keratitis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2007</year>
            <month>Oct</month>
            <day>17</day>
            <issue>4</issue>
            <fpage>CD005430</fpage>
            <pub-id pub-id-type="pmid">17943856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiseman</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Immunosuppressive Medications.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2016</year>
            <month>Feb</month>
            <day>05</day>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>332</fpage>
            <page-range>332-43</page-range>
            <pub-id pub-id-type="pmid">26170177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corbitt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nowatzky</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Inflammatory eye disease for rheumatologists.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2023</year>
            <month>May</month>
            <day>01</day>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>201</fpage>
            <page-range>201-212</page-range>
            <pub-id pub-id-type="pmid">36943695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r71">
          <label>71</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Yasir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sonthalia</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Corticosteroid Adverse Effects</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">30285357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamed</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Dighriri</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Baomar</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Alharthy</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Alenazi</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Alali</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Alenazy</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Alhumaidi</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Alhulayfi</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Alotaibi</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Alhumaidan</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Alhaddad</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Humadi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Alzahrani</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Alobaid</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Overview of Methotrexate Toxicity: A Comprehensive Literature Review.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>9</issue>
            <fpage>e29518</fpage>
            <pub-id pub-id-type="pmid">36312688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varma</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Subba</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Madhoosudanan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>CYCLOPHOSPHAMIDE INDUCED HAEMORRHAGIC CYSTITIS (A Case Report).</article-title>
            <source>Med J Armed Forces India</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-60</page-range>
            <pub-id pub-id-type="pmid">28775418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horning</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Azathioprine-Induced Rapid Hepatotoxicity.</article-title>
            <source>J Pharm Technol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-20</page-range>
            <pub-id pub-id-type="pmid">34860888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Risk of tuberculosis in patients treated with TNF-&#x003b1; antagonists: a systematic review and meta-analysis of randomised controlled trials.</article-title>
            <source>BMJ Open</source>
            <year>2017</year>
            <month>Mar</month>
            <day>22</day>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>e012567</fpage>
            <pub-id pub-id-type="pmid">28336735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r76">
          <label>76</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Bacterial Keratitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">34662023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidari</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Rheumatoid Arthritis: Early diagnosis and treatment outcomes.</article-title>
            <source>Caspian J Intern Med</source>
            <year>2011</year>
            <season>Winter</season>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>161</fpage>
            <page-range>161-70</page-range>
            <pub-id pub-id-type="pmid">24024009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stamate</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>T&#x00103;taru</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Zemba</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Emergency penetrating keratoplasty in corneal perforations.</article-title>
            <source>Rom J Ophthalmol</source>
            <year>2018</year>
            <season>Oct-Dec</season>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>253</fpage>
            <page-range>253-259</page-range>
            <pub-id pub-id-type="pmid">30891520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shanmugam</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Angra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rahimi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McNish</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Vasculitic and autoimmune wounds.</article-title>
            <source>J Vasc Surg Venous Lymphat Disord</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>280</fpage>
            <page-range>280-292</page-range>
            <pub-id pub-id-type="pmid">28214498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ting</surname>
                <given-names>DSJ</given-names>
              </name>
              <name>
                <surname>Cairns</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gopal</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Krstic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Elsahn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lister</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Said</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Dua</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors, Clinical Outcomes, and Prognostic Factors of Bacterial Keratitis: The Nottingham Infectious Keratitis Study.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>715118</fpage>
            <pub-id pub-id-type="pmid">34458289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r81">
          <label>81</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Czyz</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Mahabadi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Havens</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <chapter-title>Corneal Graft Rejection</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">30085585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Bentum</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Van den Berg</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Van der Bijl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Verbraak</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>van der Horst-Bruinsma</surname>
                <given-names>IE</given-names>
              </name>
            </person-group>
            <article-title>Multidisciplinary management of auto-immune ocular diseases in adult patients by ophthalmologists and rheumatologists.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>99</volume>
            <issue>2</issue>
            <fpage>e164</fpage>
            <page-range>e164-e170</page-range>
            <pub-id pub-id-type="pmid">32749781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Venugopal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bagga</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Christy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Prajna</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vanathi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Narayana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sahu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title><italic>Pythium insidiosum</italic> keratitis - A review.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>70</volume>
            <issue>4</issue>
            <fpage>1107</fpage>
            <page-range>1107-1120</page-range>
            <pub-id pub-id-type="pmid">35325996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lalgudi</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Shekhawat</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Venugopal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gubert</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pythium insidiosum Keratitis: Past, Present, and Future.</article-title>
            <source>Ophthalmol Ther</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>1629</fpage>
            <page-range>1629-1653</page-range>
            <pub-id pub-id-type="pmid">35788551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r85">
          <label>85</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Therapeutic Keratoplasty</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">37276297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Narayana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Christy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gubert</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Successful management of pediatric pythium insidiosum keratitis with cyanoacrylate glue, linezolid, and azithromycin: Rare case report.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>NP87</fpage>
            <page-range>NP87-NP91</page-range>
            <pub-id pub-id-type="pmid">33779337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Twinkling Eye -A Rare Presentation in Neovascular Glaucoma.</article-title>
            <source>J Glaucoma</source>
            <year>2019</year>
            <month>May</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">31135586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulbuddhe</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Addya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic Ophthalmia: Where Do We Currently Stand on Treatment Strategies?</article-title>
            <source>Clin Ophthalmol</source>
            <year>2021</year>
            <volume>15</volume>
            <fpage>4201</fpage>
            <page-range>4201-4218</page-range>
            <pub-id pub-id-type="pmid">34707340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r89">
          <label>89</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gupta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <chapter-title>Pediatric Cataract</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>6</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">34283446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Venugopal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ravindran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Uduman</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Management of symblepharon with Gore-tex as a novel treatment option for ocular chemical burns.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2024</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>1865</fpage>
            <page-range>1865-1874</page-range>
            <pub-id pub-id-type="pmid">38444229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r91">
          <label>91</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Contact Lens&#x02013;Related Complications</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">36512659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Devy</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Atypical optic neuritis - a case with a new surprise every visit.</article-title>
            <source>GMS Ophthalmol Cases</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>Doc11</fpage>
            <pub-id pub-id-type="pmid">32269909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Christy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Narayana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gubert</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Retrospective multifactorial analysis of <italic>Pythium keratitis</italic> and review of literature.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2021</year>
            <month>May</month>
            <volume>69</volume>
            <issue>5</issue>
            <fpage>1095</fpage>
            <page-range>1095-1101</page-range>
            <pub-id pub-id-type="pmid">33913840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r94">
          <label>94</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gabros</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nessel</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Zito</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <chapter-title>Topical Corticosteroids</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">30422535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Nispen</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Virgili</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hoeben</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Langelaan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klevering</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keunen</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>van Rens</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Low vision rehabilitation for better quality of life in visually impaired adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>Jan</month>
            <day>27</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD006543</fpage>
            <pub-id pub-id-type="pmid">31985055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cross</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Petrie</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kuruvilla</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Interventions for improving medication-taking ability and adherence in older adults prescribed multiple medications.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>May</month>
            <day>08</day>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>CD012419</fpage>
            <pub-id pub-id-type="pmid">32383493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amador-Patarroyo</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Jalil-Florencia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Otero-Marquez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Molano-Gonzalez</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mantilla</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Rojas-Villarraga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anaya</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Barraquer-Coll</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Can Appropriate Systemic Treatment Help Protect the Cornea in Patients With Rheumatoid Arthritis? A Multidisciplinary Approach to Autoimmune Ocular Involvement.</article-title>
            <source>Cornea</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>235</fpage>
            <page-range>235-241</page-range>
            <pub-id pub-id-type="pmid">29176449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parikh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tucci</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Galwankar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Infections of the nervous system.</article-title>
            <source>Int J Crit Illn Inj Sci</source>
            <year>2012</year>
            <month>May</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>82</fpage>
            <page-range>82-97</page-range>
            <pub-id pub-id-type="pmid">22837896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r99">
          <label>99</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Maghsoudlou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Akhondi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <chapter-title>Cornea Transplantation</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">30969512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenblum</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gratz</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Paw</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Abbas</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Treating human autoimmunity: current practice and future prospects.</article-title>
            <source>Sci Transl Med</source>
            <year>2012</year>
            <month>Mar</month>
            <day>14</day>
            <volume>4</volume>
            <issue>125</issue>
            <fpage>125sr1</fpage>
            <pub-id pub-id-type="pmid">22422994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r101">
          <label>101</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Willmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Melanson</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Corneal Injury</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">29083785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glover</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>TRR</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of Ocular Manifestations in Autoimmune Disease.</article-title>
            <source>Front Immunol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>744396</fpage>
            <pub-id pub-id-type="pmid">34795665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radu</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Bungau</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Management of Rheumatoid Arthritis: An Overview.</article-title>
            <source>Cells</source>
            <year>2021</year>
            <month>Oct</month>
            <day>23</day>
            <volume>10</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">34831081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Michelson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Newman-Casey</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Medication Adherence Among Patients With Corneal Diseases.</article-title>
            <source>Cornea</source>
            <year>2021</year>
            <month>Dec</month>
            <day>01</day>
            <volume>40</volume>
            <issue>12</issue>
            <fpage>1554</fpage>
            <page-range>1554-1560</page-range>
            <pub-id pub-id-type="pmid">33661137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Paik</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Outpatient Follow-Up Visit after Hospital Discharge Lowers Risk of Rehospitalization in Patients with Schizophrenia: A Nationwide Population-Based Study.</article-title>
            <source>Psychiatry Investig</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>425</fpage>
            <page-range>425-33</page-range>
            <pub-id pub-id-type="pmid">26508952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kampik</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Imaging in ophthalmology and need for slit-lamp and ophthalmoscopy examinations.</article-title>
            <source>Oman J Ophthalmol</source>
            <year>2016</year>
            <season>May-Aug</season>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>79</fpage>
            <pub-id pub-id-type="pmid">27433032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140253.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Babiker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>El Husseini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al Nemri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al Frayh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al Juryyan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Faki</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Assiri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al Saadi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shaikh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Al Zamil</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Health care professional development: Working as a team to improve patient care.</article-title>
            <source>Sudan J Paediatr</source>
            <year>2014</year>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>9</fpage>
            <page-range>9-16</page-range>
            <pub-id pub-id-type="pmid">27493399</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
